Through the looking glass: a positive inotropic drug and ischemic preconditioning.
Vander Heide
R S
RS
Marsh
J D
JD
D015720:5'-Nucleotidase / Q000502:physiology; D000241:Adenosine / Q000378:metabolism; D000818:Animals; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004285:Dogs; D017277:Drug Approval; D004789:Enzyme Activation / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D019157:Ischemic Preconditioning, Myocardial; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D009503:Neutropenia / Q000139:chemically induced; D011493:Protein Kinase C / Q000502:physiology; D011719:Pyrazines; D011804:Quinolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015290:Second Messenger Systems
D002316:Cardiotonic Agents; D011719:Pyrazines; D011804:Quinolines; C041667:vesnarinone; D011493:Protein Kinase C; D015720:5'-Nucleotidase; D000241:Adenosine